Market Cap (In USD)
53.19 Million
Revenue (In USD)
2.08 Million
Net Income (In USD)
-5.48 Million
Avg. Volume
206.45 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 2.22-9.595
- PE
- -6.75
- EPS
- -0.71
- Beta Value
- 0.416
- ISIN
- US67092M2089
- CUSIP
- 67092M208
- CIK
- 1676047
- Shares
- 11106200.0
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Gareth Sheridan
- Employee Count
- -
- Website
- https://nutriband.com
- Ipo Date
- 2021-10-01
- Details
- Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
More Stocks
-
3341
-
EVGRUEvergreen Corporation
EVGRU
-
WM
-
ASTERDMAster DM Healthcare Limited
ASTERDM
-
000820
-
TXAR
-
GLNLFGalan Lithium Limited
GLNLF
-
601900